The Impact of Dexmedetomidine on the Cardiac Electrophysiological Properties in Patients With Paroxysmal Atrial Fibrillation

Trial Profile

The Impact of Dexmedetomidine on the Cardiac Electrophysiological Properties in Patients With Paroxysmal Atrial Fibrillation

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2016

At a glance

  • Drugs Dexmedetomidine (Primary)
  • Indications Paroxysmal atrial fibrillation
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top